SUBSEQUENT EVENT	6 Months Ended
Jun. 30, 2020
Subsequent Events [Abstract]
SUBSEQUENT EVENT	SUBSEQUENT EVENT On August 6, 2020, the Company announced that it intends to spin off its eye-health business into an independent publicly traded entity (“NewCo”) from the remainder of Bausch Health. The spinoff will establish two separate companies that include: •.A fully integrated, pure play eye-health company built on the iconic Bausch + Lomb brand and long history of innovation; and •.A diversified pharmaceutical company with leading positions in gastroenterology, aesthetics/dermatology, neurology and international pharmaceuticals. NewCo, will consist of Bausch Health’s global vision care, surgical, consumer and ophthalmic Rx businesses. The remaining Bausch Health business, will comprise a diversified portfolio of leading durable brands across the Salix, International Rx, Solta, neurology and medical dermatology businesses. The timing of the anticipated spinoff will be subject to certain conditions, including final approval by the Company’s Board of Directors and any shareholder vote requirements that may be applicable. There can be no assurance that a transaction will occur.

SUBSEQUENT EVENT

6 Months Ended

Jun. 30, 2020

On August 6, 2020, the Company announced that it intends to spin off its eye-health business into an independent publicly traded entity (“NewCo”) from the remainder of Bausch Health. The spinoff will establish two separate companies that include:

•.A fully integrated, pure play eye-health company built on the iconic Bausch + Lomb brand and long history of innovation; and

•.A diversified pharmaceutical company with leading positions in gastroenterology, aesthetics/dermatology, neurology and international pharmaceuticals.

NewCo, will consist of Bausch Health’s global vision care, surgical, consumer and ophthalmic Rx businesses. The remaining Bausch Health business, will comprise a diversified portfolio of leading durable brands across the Salix, International Rx, Solta, neurology and medical dermatology businesses. The timing of the anticipated spinoff will be subject to certain conditions, including final approval by the Company’s Board of Directors and any shareholder vote requirements that may be applicable. There can be no assurance that a transaction will occur.